MetaGraph compresses vast data archives into a search engine for scientists, opening up new frontiers of biological discovery ...

“Our findings show that RNA-based testing can uncover hidden risks in multiple myeloma that DNA tests alone miss,” study ...

The Company continues to expand its current ADC pipeline to encompass multiple targets, such as AKTX-101 (Trop2 ADC with PH1 payload), as well as future programs (AKTX-102, undisclosed target with PH1 ...

By examining genomic variation more closely, scientists can now identify new disease connections with greater speed and accuracy. For centuries, scientists have recognized that certain illnesses can ...

BMS agreed to pay $1.5 billion to acquire Orbital. With the acquisition, the Big Pharma firm will inherit a multitude of ...

DM1 cohort recruitment completion in Q4 2025, topline data in mid-2026, and potential BLA filing for z-basivarsen in late ...

The Neuromuscular Disease Therapeutics Market is entering a period of accelerated growth, supported by breakthroughs in gene ...

Robust improvement demonstrated across diverse set of clinical measures -- Patient-reported outcomes support clinical meaningfulness of ...

RNA-binding proteins (RBPs) are central regulators of post-transcriptional gene expression. They modulate key aspects of mRNA metabolism—such as splicing, ...

Alida Biosciences’ EpiPlex platform uses robust assay controls and specialized bioinformatics to detect RNA modification, genomic coordinates, and relative quantity.

Unlike current ADCs that use tubulin inhibitors and DNA damaging agents as their payloads, PH1 is a novel payload that is a ...

University of Michigan researchers have developed a tool powered by artificial intelligence that can help them examine the ...